PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 135 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $555 | +20.4% | 15,800 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $461 | +41.4% | 15,800 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $326 | +20.3% | 15,800 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $271 | -38.1% | 15,800 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $438 | +22.7% | 15,800 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $357 | +131.8% | 15,800 | 0.0% | 0.00% | – |
| Q4 2022 | $154 | -99.9% | 15,800 | 0.0% | 0.00% | – |
| Q3 2022 | $131,000 | -6.4% | 15,800 | 0.0% | 0.00% | – |
| Q2 2022 | $140,000 | -63.0% | 15,800 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $378,000 | -13.9% | 15,800 | +9.7% | 0.00% | 0.0% |
| Q4 2021 | $439,000 | +78.5% | 14,400 | +2.9% | 0.00% | 0.0% |
| Q3 2021 | $246,000 | -60.1% | 14,000 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $616,000 | +74.0% | 14,000 | 0.0% | 0.00% | +100.0% |
| Q1 2021 | $354,000 | +18.0% | 14,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $300,000 | – | 14,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $43,253,000 | 8.50% |
| BVF INC/IL | 2,367,288 | $41,806,000 | 2.58% |
| RTW INVESTMENTS, LP | 3,383,208 | $59,747,000 | 1.68% |
| Novo Holdings A/S | 824,169 | $14,555,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,013,495 | $17,898,000 | 0.52% |
| Sofinnova Investments, Inc. | 326,064 | $5,758,000 | 0.36% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,500,000 | $44,150,000 | 0.35% |
| Virtus ETF Advisers LLC | 21,639 | $382,000 | 0.18% |
| Baker Brothers Advisors | 1,911,446 | $33,756,000 | 0.15% |
| King Wealth Management Group | 22,000 | $389,000 | 0.11% |